Get the Stockscreener App
15.00
1.57%
-0.24
Range Cancer Therapeutics ETF Stock (CNCR) Forecast
The Range Cancer Therapeutics ETF (CNCR) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $15.47, representing a +3.10% increase from the current price of $15.00. The highest analyst price target is $16.48, and the lowest is $14.45.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month CNCR Price Target
Average 13.54
(-9.71% Downside)
Is Range Cancer Therapeutics ETF (CNCR) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 47.06 | Neutral |
| STOCH(9,6) | 72.22 | Neutral |
| STOCHRSI(14) | 55.76 | Neutral |
| MACD(12,26) | -0.0211 | Buy |
| ADX(14) | 17.60 | Neutral |
| William %R | -40.19 | Neutral |
| CCI(14) | 11.52 | Neutral |
Buy: 1
Sell: 0
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
15.38
Sell
|
15.27
Sell
|
| MA20 |
14.89
Buy
|
15.23
Sell
|
| MA50 |
15.75
Sell
|
15.30
Sell
|
| MA100 |
15.13
Sell
|
14.82
Buy
|
| MA200 |
13.16
Buy
|
14.10
Buy
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, CNCR could be considered a Neutral, with 17 technical analysis indicators signaling 5 Buy signals, 6 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on CNCR, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 47.06 indicates that CNCR is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 72.22 indicates that CNCR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 55.76 indicates that CNCR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 17.6 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 11.52 indicates that CNCR is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term CNCR price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Range Cancer Therapeutics ETF financial reports and earnings history, Range Cancer Therapeutics ETF (CNCR) stock could reach $11.59 by 2030, $1.9585 by 2040 and $2.6909 by 2050. See the projected annual prices until 2050 of the Range Cancer Therapeutics ETF stock below:
- Range Cancer Therapeutics ETF (CNCR) is expected to reach an average price of $3.6468 in 2035, with a high prediction of $3.6468 and a low estimate of $1.8145. This indicates an $-75.69% rise from the last recorded price of $15.00.
- Range Cancer Therapeutics ETF (CNCR) stock is projected to chart a bullish course in 2040, with an average price target of $1.4785, representing an $-90.14% surge from its current level. The forecast ranges from a conservative $0.422 to a sky-high $1.9585.
- Our analysts predict Range Cancer Therapeutics ETF (CNCR) to jump -90.66% by 2045, soaring from $1.4013 to an average price of $1.4013, potentially reaching $1.4388. While $1.4013 is the low estimate, the potential upside is significant.
- Range Cancer Therapeutics ETF (CNCR) stock is expected to climb by 2050, reaching an average of $3.5409, a $-76.39% jump from its current level. However, a wide range of estimates exists, with high and low targets of $2.6909 and $2.6412, respectively, highlighting the market's uncertainty.
Range Cancer Therapeutics ETF Stock (CNCR) Year by Year Forecast
Range Cancer Therapeutics ETF Stock (CNCR) Price Forecast for 2024
Our forecast for CNCR stock price in 2024 now indicates an average price target of $15.99 with a high forecast of $18.99 and a low forecast of $12.99. The average prediction reflects an increase of +6.63% from the last recorded price of $15.00.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| June, 2024 | $16.22 | $14.45 | $16.48 | +8.12% |
| July, 2024 | $16.71 | $15.97 | $16.85 | +11.37% |
| August, 2024 | $14.49 | $14.49 | $16.78 | -3.37% |
| September, 2024 | $15.47 | $14.15 | $15.47 | +3.11% |
| October, 2024 | $13.83 | $12.99 | $15.56 | -7.79% |
| November, 2024 | $15.60 | $13.91 | $15.70 | +3.98% |
| December, 2024 | $18.75 | $15.70 | $18.99 | +25.03% |
Range Cancer Therapeutics ETF Stock (CNCR) Price Forecast for 2025
Range Cancer Therapeutics ETF Stock (CNCR) is expected to reach an average price of $16.47 in 2025, with a high prediction of $25.67 and a low estimate of $7.2788. This indicates an +9.82% rise from the last recorded price of $15.00.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $18.44 | $18.13 | $19.71 | +22.96% |
| February, 2025 | $16.30 | $16.19 | $19.81 | +8.67% |
| March, 2025 | $16.44 | $16.01 | $18.03 | +9.58% |
| April, 2025 | $14.82 | $7.2788 | $18.20 | -1.20% |
| May, 2025 | $19.05 | $13.99 | $19.63 | +27.02% |
| June, 2025 | $21.38 | $17.06 | $21.43 | +42.53% |
| July, 2025 | $22.27 | $20.27 | $23.33 | +48.46% |
| August, 2025 | $22.36 | $21.92 | $23.43 | +49.04% |
| September, 2025 | $21.56 | $20.49 | $23.91 | +43.74% |
| October, 2025 | $20.33 | $19.38 | $22.60 | +35.55% |
| November, 2025 | $22.87 | $20.22 | $24.54 | +52.46% |
| December, 2025 | $21.64 | $21.60 | $25.67 | +44.25% |
Range Cancer Therapeutics ETF Stock (CNCR) Price Forecast for 2026
The predicted value for Range Cancer Therapeutics ETF (CNCR) in 2026 is set at an average of $26.52. Estimates vary from a peak of $31.31 to a trough of $21.73, indicating an +76.82% surge from the present price of $15.00.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $26.98 | $21.73 | $27.02 | +79.88% |
| February, 2026 | $28.66 | $27.12 | $29.83 | +91.08% |
| March, 2026 | $30.12 | $26.92 | $30.75 | +100.83% |
| April, 2026 | $28.81 | $27.94 | $31.31 | +92.06% |
| May, 2026 | $26.76 | $23.98 | $28.51 | +78.43% |
| June, 2026 | $24.23 | $23.80 | $27.41 | +61.54% |
| July, 2026 | $25.23 | $23.44 | $26.84 | +68.20% |
| August, 2026 | $26.79 | $24.97 | $27.15 | +78.58% |
| September, 2026 | $26.96 | $25.85 | $28.57 | +79.71% |
| October, 2026 | $25.10 | $23.87 | $26.82 | +67.36% |
| November, 2026 | $26.18 | $22.89 | $26.32 | +74.53% |
| December, 2026 | $26.57 | $25.58 | $27.32 | +77.13% |
Range Cancer Therapeutics ETF Stock (CNCR) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Range Cancer Therapeutics ETF (CNCR) is $17.36, with a high forecast of $26.15 and a low forecast of $8.5704. This indicates an +15.75% increase from the last price of $15.00.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $24.39 | $24.21 | $26.06 | +62.63% |
| February, 2027 | $23.99 | $23.97 | $26.15 | +59.92% |
| March, 2027 | $21.29 | $19.69 | $23.73 | +41.92% |
| April, 2027 | $16.11 | $15.96 | $22.36 | +7.39% |
| May, 2027 | $14.47 | $13.38 | $16.28 | -3.56% |
| June, 2027 | $12.76 | $12.69 | $15.40 | -14.93% |
| July, 2027 | $13.76 | $12.03 | $14.54 | -8.26% |
| August, 2027 | $11.25 | $11.09 | $15.12 | -24.97% |
| September, 2027 | $9.7169 | $8.866 | $11.87 | -35.22% |
| October, 2027 | $11.42 | $8.5704 | $11.67 | -23.84% |
| November, 2027 | $12.39 | $10.48 | $12.87 | -17.43% |
| December, 2027 | $12.27 | $11.23 | $13.86 | -18.23% |
Range Cancer Therapeutics ETF Stock (CNCR) Price Forecast for 2028
In 2028, Range Cancer Therapeutics ETF (CNCR) is projected to reach an average price of $8.4239, with a high projection of $12.72 and a low estimate of $4.1328. This indicates an -43.84% fall from the last price of $15.00.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $11.97 | $4.1328 | $12.72 | -20.22% |
| February, 2028 | $10.45 | $9.8553 | $12.15 | -30.30% |
| March, 2028 | $10.44 | $9.9415 | $11.33 | -30.39% |
| April, 2028 | $10.83 | $10.14 | $11.73 | -27.80% |
| May, 2028 | $9.7302 | $9.0202 | $11.21 | -35.13% |
| June, 2028 | $10.88 | $9.4234 | $11.11 | -27.49% |
| July, 2028 | $10.17 | $9.8022 | $11.14 | -32.18% |
| August, 2028 | $8.233 | $8.0189 | $9.8532 | -45.11% |
| September, 2028 | $8.4192 | $7.6771 | $8.5392 | -43.87% |
| October, 2028 | $9.3055 | $8.3873 | $9.8855 | -37.96% |
| November, 2028 | $9.6857 | $8.8936 | $9.9346 | -35.43% |
| December, 2028 | $8.832 | $8.592 | $10.09 | -41.12% |
Range Cancer Therapeutics ETF Stock (CNCR) Price Forecast for 2029
The 2029 price forecast for Range Cancer Therapeutics ETF Stock (CNCR) is $9.7696 on average, with a high prediction of $14.18 and a low estimate of $5.355. This represents an -34.87% decrease from the previous price of $15.00.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $8.5323 | $8.4041 | $9.5101 | -43.12% |
| February, 2029 | $8.1185 | $7.8904 | $8.6963 | -45.88% |
| March, 2029 | $7.2147 | $7.1247 | $8.3766 | -51.90% |
| April, 2029 | $5.881 | $5.881 | $7.3288 | -60.79% |
| May, 2029 | $6.8012 | $5.355 | $6.9712 | -54.66% |
| June, 2029 | $7.9375 | $6.4553 | $8.0075 | -47.08% |
| July, 2029 | $9.5237 | $7.6915 | $10.15 | -36.51% |
| August, 2029 | $10.82 | $9.3318 | $10.93 | -27.86% |
| September, 2029 | $13.49 | $10.40 | $13.95 | -10.07% |
| October, 2029 | $12.86 | $11.99 | $14.18 | -14.26% |
| November, 2029 | $10.65 | $10.03 | $12.83 | -29.02% |
| December, 2029 | $10.60 | $9.7681 | $12.09 | -29.35% |
Range Cancer Therapeutics ETF Stock (CNCR) Price Forecast for 2030
Range Cancer Therapeutics ETF Stock (CNCR) is expected to reach an average price of $8.8021 in 2030, with a high forecast of $15.05 and a low forecast of $2.5577. This signifies an -41.32% decrease from the last price of $15.00.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $11.21 | $9.5425 | $11.59 | -25.28% |
| February, 2030 | $11.54 | $10.51 | $11.96 | -23.04% |
| March, 2030 | $10.46 | $10.27 | $11.92 | -30.24% |
| April, 2030 | $9.9767 | $9.298 | $10.65 | -33.49% |
| May, 2030 | $8.6567 | $8.1677 | $10.72 | -42.29% |
| June, 2030 | $10.13 | $8.2548 | $10.21 | -32.47% |
| July, 2030 | $13.83 | $10.31 | $13.97 | -7.81% |
| August, 2030 | $14.26 | $13.27 | $14.93 | -4.91% |
| September, 2030 | $13.84 | $13.42 | $15.05 | -7.70% |
| October, 2030 | $13.02 | $11.44 | $14.17 | -13.20% |
| November, 2030 | $8.2717 | $2.5577 | $13.47 | -44.86% |
| December, 2030 | $11.57 | $7.8758 | $11.57 | -22.87% |
0.23%
0.28%
Cap:
|
Volume (24h):